Lyfe Rx: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://thelyferx.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.

1. 1

   “The following claims concerning compounded semaglutide and tirzepatide products appear on your website:”

2. 2

   “• “Clinically Proven Weight Loss – Semaglutide has been shown to….” • “Clinically Proven Weight Loss – Tirzepatide has been shown to….””

3. 3

   “Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].”

1. 1

   Letter issued

   September 2025

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

thelyferx.com resolved on 2026-08-09 and redirected to a live 295KB storefront titled "Lyfe RX | Wellness & Weight Loss Delivered to Your Door!", with published prices on the two products the letter names (semaglutide $225.00, tirzepatide $299.00), six further protocols, a working cart, and a comparison table the site itself dates "as of August 2026". The controls run in the same pass separate a live site from a dead one: a deliberately non-existent domain failed DNS outright, and sema.bio — another recipient in this same 09/09/2025 sweep — returned 200 with a 114-byte registrar parking page. This is a check of whether the site is up and what it sells; it is not a check of anything the letter alleges.

"Clinically proven" is a phrase with a specific meaning and a specific owner. It means a drug went through controlled trials, that a regulator read them, and that the result is written into an approved label a buyer can go and read. A compounded product has none of that: it is prepared by a pharmacy for an individual patient, it has no approved label, and no trial was run on it. So the sentence borrows a standard that was earned by a different product. What makes this letter worth reading twice is where FDA's quotation stops. It cites the assertion and then the first four words of the sentence underneath — "has been shown to…." — and stops. Shown to do what, in whom, against what comparator, over how long: none of that is in the citation, because none of it was load-bearing. The header did the selling. And because the identical header ran on both product pages with only the molecule changed, it was never a statement about semaglutide or about tirzepatide; it was furniture. That is the practical test for a shopper: read the proof sentence, not the proof headline, and see whether it names a study you could look up. Checked on 2026-08-09, that language is gone from both product pages FDA named — "clinically" now appears on them only in the sense of "clinically appropriate" and "clinically authorized", describing when a provider will approve an order rather than what the drug will do. The site is trading normally at published prices. The letter concerns wording, makes no finding about how the products were made or what is in them, and FDA has not closed it out.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Lyfe Rx failed to respond.